Erenumab may represent an effective treatment strategy for individuals with highly therapy-refractory migraine, real-world evidence suggests

In this retrospective study, researchers from University Duisburg-Essen (Essen, Germany) provide the first real-world evidence from Germany concerning the clinical efficacy of erenumab amongst individuals with highly therapy-refractory migraine. Migraine is an extremely debilitating condition and represents one of the main causes of disability worldwide. Various monoclonal antibodies that target the CGRP signaling cascade have been approved as specific prophylactic therapies for migraine, with erenumab (Aimovig®, Novartis, Basel, Switzerland) representing the only approved antibody specifically against the CGRP receptor. In this new study, researchers from University Duisburg-Essen (Essen, Germany) provide the first real-world evidence from Germany concerning the clinical efficacy...